Latest:
Dr. Olopade on Moving the Needle Forward in Preventive Oncology and Genetics
Olufunmilayo I. Olopade, MD, FACP, discusses the need to focus efforts in preventive oncology and genetics.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Omid A. Hamid, MD
Omid Hamid, MD, is a professor of medicine at Cedars-Sinai. He is also director of clinical Research and Immunotherapy and director of Cutaneous Oncology and Melanoma at the The Angeles Clinic and Research Institute, both in Los Angeles, California.
Latest:
Dr Hamid on the Investigation of Fianlimab With Cemiplimab in Advanced Melanoma
Omid Hamid, MD, discusses the investigation of the LAG-3 inhibitor fianlimab in combination with cemiplimab in patients with advanced melanoma who were naïve to anti–PD-1 agents in the advanced setting.
Omid Hamid, MD
Omid Hamid, MD, is a professor of medicine at Cedars-Sinai. He is also director of clinical Research and Immunotherapy and director of Cutaneous Oncology and Melanoma at the The Angeles Clinic and Research Institute, both in Los Angeles, California.
Latest:
Dr Hamid on the Potential for Cancer Vaccines in Melanoma
Omid Hamid, MD, provides insight on the potential role of cancer vaccines in melanoma.
OncLive
Latest:
Immunotherapy Treatment Options in High-Risk or Locally Advanced/Metastatic Non-melanoma and Melanoma: An Evolving Treatment Landscape
On April 4, 2025, a select group of international experts in dermatologic oncology participated in a live workshop to discuss treatment options in high-risk or locally advanced/metastatic melanoma and non-melanoma skin cancers in an evolving treatment landscape. Caroline Robert, MD, PhD, led the discussion, obtaining perspectives on the available evidence about immunotherapy options and insights into treatment preferences for high-risk cutaneous squamous cell carcinoma that is either locally advanced (laCSCC) or metastatic (mCSCC) and advanced/metastatic cutaneous melanoma.
OncLive Staff Writer
Latest:
FDA Accepts Sacituzumab Govitecan Application for TNBC
The FDA has accepted a biologics license application for sacituzumab govitecan as a treatment for patients with metastatic triple-negative breast cancer who have received at least 2 prior therapies for metastatic disease.
Ophira M. Ginsburg, MSc, MD, FRCPC
Latest:
Dr. Ginsburg on Determining Genetic Testing in Gynecologic Malignancies
Ophira M. Ginsburg, MSc, MD, FRCPC, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, discusses determining which patients should receive genetic testing for gynecologic malignancies.